This phase II, 43 patient trial, will evaluate the efficacy of GTI-2040, an antisense oligonucleotide complementary to the R2 component of ribonucleotide reductase (RNR) mRNA, in combination with capecitabine, in the setting of advanced/metastatic renal cell carcinoma. Preclinical studies have shown synergy between GTI-2040 and capecitabine against renal cell carcinoma.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
43
Bay Area Cancer Research Group
Concord, California, United States
USC-Norris Comprehensive Cancer Center and Hospital
Los Angeles, California, United States
CA Hematology Oncology Medical Group
Torrance, California, United States
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Innovative Medical Research of South Florida, Inc.
Miami Shores, Florida, United States
University of Chicago Medical Center
Chicago, Illinois, United States
Ochsner Clinic Foundation
New Orleans, Louisiana, United States
SUNY Upstate Medical University
Syracuse, New York, United States
Comprehensive Cancer Center of Wake Forest University
Winston-Salem, North Carolina, United States
The Cleveland Clinic Foundation
Cleveland, Ohio, United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States